Tibet Weixinkang Medicine Co Ltd Market Cap ($524.71 Million)
Market Cap & Net Worth: Tibet Weixinkang Medicine Co Ltd (603676)
Tibet Weixinkang Medicine Co Ltd market cap. Tibet Weixinkang Medicine Co Ltd (SHG:603676) has a market capitalization of $524.71 Million (CN¥3.59 Billion) as of November 9, 2026. Listed on the SHG stock exchange, this China-based company holds position #11630 globally and #3297 in its home market, demonstrating a -1.55% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tibet Weixinkang Medicine Co Ltd's stock price CN¥8.24 by its total outstanding shares 435161500 (435.16 Million). Also see 603676 cash generation efficiency for how efficiently the company converts equity into cash flow.
Tibet Weixinkang Medicine Co Ltd Market Cap History (2017–2026)
Tibet Weixinkang Medicine Co Ltd market cap history from 2017 to 2026. Data shows growth from $965.57 Million to $524.71 Million (0.98% CAGR). Check 603676 share price today for real-time trading data and today's change.
Tibet Weixinkang Medicine Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tibet Weixinkang Medicine Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Tibet Weixinkang Medicine Co Ltd growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.59x
Tibet Weixinkang Medicine Co Ltd's market cap is 0.59 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.88x
Tibet Weixinkang Medicine Co Ltd's market cap is 2.88 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $965.57 Million | $420.38 Million | $101.59 Million | 2.30x | 9.50x |
| 2018 | $680.80 Million | $746.32 Million | $73.44 Million | 0.91x | 9.27x |
| 2019 | $644.17 Million | $740.96 Million | $55.68 Million | 0.87x | 11.57x |
| 2020 | $548.17 Million | $715.67 Million | $58.42 Million | 0.77x | 9.38x |
| 2021 | $572.83 Million | $1.03 Billion | $95.91 Million | 0.55x | 5.97x |
| 2022 | $997.44 Million | $1.40 Billion | $176.96 Million | 0.71x | 5.64x |
| 2023 | $664.16 Million | $1.32 Billion | $214.02 Million | 0.50x | 3.10x |
| 2024 | $633.59 Million | $1.30 Billion | $246.17 Million | 0.49x | 2.57x |
| 2025 | $669.89 Million | $1.14 Billion | $232.85 Million | 0.59x | 2.88x |
Competitor Companies of 603676 by Market Capitalization
Companies near Tibet Weixinkang Medicine Co Ltd in the global market cap rankings as of November 9, 2026. Also see balance sheet size of Tibet Weixinkang Medicine Co Ltd for a full breakdown of the balance sheet.
Key companies related to Tibet Weixinkang Medicine Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #530 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #567 globally with a market cap of $47.07 Billion USD ( CN¥321.69 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #609 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.57 |
| #567 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $47.07 Billion | CN¥50.43 |
| #609 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.80 |
Market Capitalization of Tibet Weixinkang Medicine Co Ltd (2017–2026)
Market capitalization of Tibet Weixinkang Medicine Co Ltd from 2017 to today. Between 2017 and today, Tibet Weixinkang Medicine Co Ltd's market cap moved from $965.57 Million to $ 524.71 Million, with a yearly change of 0.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥524.71 Million | -21.67% |
| 2025 | CN¥669.89 Million | +5.73% |
| 2024 | CN¥633.59 Million | -4.60% |
| 2023 | CN¥664.16 Million | -33.41% |
| 2022 | CN¥997.44 Million | +74.13% |
| 2021 | CN¥572.83 Million | +4.50% |
| 2020 | CN¥548.17 Million | -14.90% |
| 2019 | CN¥644.17 Million | -5.38% |
| 2018 | CN¥680.80 Million | -29.49% |
| 2017 | CN¥965.57 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 9th, 2026 the market cap of Tibet Weixinkang Medicine Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $524.71 Million USD |
| MoneyControl | $524.71 Million USD |
| MarketWatch | $524.71 Million USD |
| marketcap.company | $524.71 Million USD |
| Reuters | $524.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tibet Weixinkang Medicine Co Ltd
Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of chemical drugs and their bulk drugs in China. It offers APIs; multivitamins and pediatric multivitamins for injections; concentrate of trace elements solution for infusion; compound and pediatric compound amino acid injections; iron sucrose, multiple electrolytes, potassium aspartate and magnesium… Read more